Evidence map›Paper›PMID 39810529›Full record

ArticleCombinatorial chemistry & high throughput screening2025

Mechanism of Qilong Capsule against Myocardial Ischemia-Reperfusion Injury Based on Network Pharmacology and Experimental Validation.

Lingxu Li, Jingxue Ye, Jiahui Zhou, Zhihui Wang, Ruoyun Li, Min Wang, Guibo Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lingxu LiKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100193, China.
Jingxue YeKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100193, China.
Jiahui ZhouKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100193, China.
Zhihui WangKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100193, China.
Ruoyun LiKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100193, China.
Min WangKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100193, China.
Guibo SunKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100193, China.

Funding

CAMS Innovation Fund for Medical Sciences (CIFMS) 2022-I2M-2-001National Natural Science Foundation of China 82030124
6 · The paper itself

Abstract

introductionQilong capsule (QC) has been used clinically to treat ischemic stroke in China. This study evaluated the therapeutic effects of QC on myocardial ischemia-reperfusion injury (MIRI) and its potential mechanisms.

methodThe components and candidate targets of QC against MIRI were predicted by network pharmacology via relevant databases such as TCMSP, BATMAN-TCM, GeneCards. The potential mechanisms were predicted by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses and verified by enzyme-linked immunosorbent assay (ELISA) and Western blot.

resultsNetwork pharmacology analysis indicated that the cardioprotective effect of QC against MIRI was associated with inflammatory pathways. We further confirmed that QC effectively decreased the levels of inflammatory factors, including hs-CRP and MCP-1, and suppressed the expression of TNF-α and the phosphorylation of STAT3.

conclusionThis study provides evidence for further clinical applications of QC for MIRI therapy.

Indexed as

Drugs, Chinese HerbalMyocardial Reperfusion InjuryNetwork PharmacologyAnimalsCapsulesHumansSTAT3 Transcription FactorCapsulesDrugs, Chinese HerbalQilongSTAT3 Transcription FactorChinese medicineheartinflammationmyocardial ischemia-reperfusion injuryqilong capsuleSTAT3.

Identifiers

PMID39810529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.